Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

The IPO, which saw 25 million shares sold at $16, in the middle of the $15 to $17 range predicted by the company, continues a ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. Biotech listings saw their heyday in the middle of the COVID-19 pandemic, when an incredible 87 U.S.-based drug developers ...

US biotech Generate Biomedicines (Nasdaq: GENB) raised $400 million in its initial public offering, selling 25 million shares at $16 each, the midpoint of its range. It marks the largest biotech IPO ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. | Gilead penned a potential ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

Promoted by Dr Krishna Ella, the vaccine manufacturer serves both domestic and export markets and remains entirely ...

Bharat Biotech is seeking to raise over $500 million through an IPO. Discussions are ongoing, and details may change. Established in 1996, the company has distributed over 9 billion vaccines worldwide ...

Bharat Biotech is considering a $500 million IPO, aiming to expand its vaccine portfolio. Learn about its global impact and ...

While the first couple months of the year brought a steady stream of market entries from companies in sectors such as construction tech, space tech and biotech, new offerings from SaaS companies, long ...